#Taiwan #Taipei #Formosa Pharmaceuticals #Clobetasol Propionate #Apotex Inc

Formosa Pharmaceuticals Partners with Apotex for Ocular Care in Mexico

In a significant move to enhance ocular care in Mexico, Formosa Pharmaceuticals, a Taiwanese biotechnology firm, announced its exclusive licensing agreement with Apotex Inc. This partnership is aimed at commercializing clobetasol propionate ophthalmic suspension, branded as APP13007, which is designed specifically for managing inflammation and pain following ocular surgery. The agreement is a strong step forward for both companies, particularly as they endeavor to improve post-surgical recovery for patients and expand their footprint in the pharmaceutical market.

Innovative Treatment for Eye Care

The clobetasol propionate ophthalmic suspension is a 0.05% formulation recognized for its potency in treating ocular inflammation. It was approved by the U.S. Food and Drug Administration (FDA) in 2024. The innovative aspect of APP13007 lies in its formulation, developed using Formosa’s proprietary APNT® nanoparticle technology. This technology enhances the delivery and effectiveness of medication, allowing for rapid and sustained relief from inflammation and pain.

Clinical trials have indicated that APP13007 has statistically significant advantages in efficacy compared to placebo (p<0.001), underlining its potential importance for patients requiring post-operative care. The superpotent corticosteroid component ensures a robust therapeutic response, making it an ideal choice for ophthalmologists treating patients post-surgery.

Expanding Access in Mexico

The collaboration between Formosa and Apotex was initiated in 2024 but is now seeing expansion into Mexican markets. Erick Co, the President and CEO of Formosa Pharmaceuticals, expressed excitement about the partnership, emphasizing the positive experience with Apotex’s Canadian operations. He stated, "Our experience with Apotex’s Canadian team underscored their commitment to branded and differentiated ophthalmology products, giving us full confidence that APP13007 will reach ophthalmologists and patients in Mexico as swiftly as possible."

The move is timely, as Apotex highlights its commitment to improving access to essential medicines and health products. Alok Kanti, President of Apotex International, remarked on the importance of partnerships in expanding access to innovative treatments, indicating that adding APP13007 to their portfolio reflects a strategic push for growth in the Americas.

About Formosa Pharmaceuticals

Formosa Pharmaceuticals, Inc. (6838.TW) focuses on developing therapeutic innovations in ophthalmology and oncology. With cutting-edge nanoparticle formulation technology, the company aims to overcome challenges associated with drug delivery and bioavailability. The ability to efficiently deliver potent drugs and enhance stability and uniformity has positioned Formosa as a leader in biotechnology.

To learn more about their advancements in drug formulation and production, visit Formosa Pharma.

About Apotex Inc.

Apotex Inc. stands as a pivotal player in the global pharmaceutical industry, with its headquarters in Toronto and operational reach across numerous countries, including the United States, Mexico, and India. Recognized for providing affordable, innovative health solutions, Apotex serves millions of patients worldwide. For further details on their extensive product range and initiatives, explore Apotex.

In conclusion, the exclusive licensing agreement between Formosa Pharmaceuticals and Apotex Inc. heralds a promising shift for ocular health treatments in Mexico, facilitating easier access to a state-of-the-art solution for managing post-ocular surgery care.